Tilray's New Brew: How Beer and Pharma Distribution Are Redefining a Cannabis Pure-Play
The Pivot from Cannabis to Consumer Products
When Tilray Brands reported fiscal 2026 results on July 28, the headline wasn't cannabis — it was beer. The company that began as a cannabis pure-play has transformed into a diversified global consumer products and pharmaceutical distribution business, and the earnings call made that unmistakable. “Today, Tilray is a diversified global consumer products and pharmaceutical distribution company with leadership positions across cannabis, beverage, hospitality and wellness.” — Irwin Simon, Chief Executive Officer · 2026-07-28 The strategic pivot is not just rhetoric; it's reflected in the numbers. Fiscal 2026 revenue hit a record $915.5 million, up 11% organically and from acquisitions, and adjusted EBITDA rose 11% to $61.1 million. CFO Carl Merton noted, “Net revenue increased 11% in fiscal 2026, both organically and from acquisitions, to a record $915.5 million” — Carl Merton, Chief Financial Officer · 2026-07-28, but the real story is the mix shift.
The transformation has been years in the making. In the early days of Tilray, the company was synonymous with cannabis cultivation. But as the Canadian market matured and price compression hit, management aggressively diversified. The acquisitions of SweetWater, Montauk, and the ABI brands built a craft beer platform; the purchase of CC Pharma in Germany added a pharmaceutical distribution network; and most recently, the $54 million acquisition of BrewDog brought in a global beverage business and a hospitality footprint of 37 pubs. The pharmaceutical distribution arm now reaches 16,000 pharmacies in Germany, and the international cannabis business grew 34% to $84.9 million. “We have brands, we have manufacturing facilities, 93% of our products are made by ourselves” — Irwin Simon, Chief Executive Officer · 2026-07-28, CEO Irwin Simon emphasized during Q&A, underscoring the vertical integration that now defines the company.
World Cup as a Catalyst for Hospitality
The World Cup was a tangible proof point for Tilray's hospitality strategy. The company's flagship BrewDog Waterloo pub sold out every England match, generating approximately £412,000 in incremental revenue above budget and welcoming over 28,000 pre-booked guests. This is not a side project; it's a deliberate channel for brand building and consumer engagement.
The World Cup activation also showcased the cross-selling potential: American craft beers accounted for 58% of guest beer sales, with Shock Top leading the way. This is the kind of operational synergy that the market has yet to price in.Our pubs are far more than hospitality assets. They're powerful consumer engagement platforms that strengthen our brands, deepens consumer loyalty, generates valuable consumer insights and creates experience that most beverage companies simply cannot replicate.
Balance Sheet Strength in a Down Market
Despite the strategic progress, the stock has been under pressure. The recent 90-day price action shows a 26.3% decline, and the full history is a staggering 99.8% drawdown from the 2018 peak. Yet the balance sheet tells a different story. The company ended fiscal 2026 with approximately $235 million in cash and marketable securities, net debt of less than $1 million, and a 95% year-over-year improvement in net debt. Revenue has climbed to over $200 million per quarter, yet the price-to-sales multiple has compressed to under 1x — a stark contrast to the growth narrative. Management is acutely aware of this disconnect. In the prepared remarks, Simon said, “We continue to believe the market has not fully recognizing the value of what we've built.” — Irwin Simon, Chief Executive Officer · 2026-07-28
The company's distribution system — spanning 900 distributors in the U.S. and pharmacy networks in Europe — is an asset that could unlock value if U.S. rescheduling creates a federal path for cannabis. Simon reiterated that Tilray would be ready with supply, brands, and research. But the near-term momentum is coming from beverages and wellness. The Carlsberg partnership, beginning January 1, 2027, will add a national brand to the U.S. portfolio, and BrewDog is expected to be margin-accretive. Management guides fiscal 2027 adjusted EBITDA to $68–75 million, a double-digit increase from fiscal 2026.
The prior calls foreshadowed this evolution. In January, Simon said, “Our plan is to leverage the infrastructure and expertise and know-how that we've developed that we got a $150 million business in Tilray today” — Irwin Simon, CEO · 2026-01-08 — referring to the global medical cannabis and pharmaceutical distribution platform. And in October, he noted, “we have over 5 million square feet” — Irwin Simon, Chief Executive Officer · 2025-10-09 of cultivation space, a reminder that the cannabis roots remain a core optionality.
Why This Matters Now
Tilray is no longer a bet on a single regulatory outcome. It has built a diversified engine that could compound growth across cannabis, beer, spirits, wellness, and pharma distribution. The stock price, however, remains trapped in a drawdown, reflecting persistent skepticism about execution and the competitive landscape. The next 12 months will be pivotal: Can the company deliver on the EBITDA guidance? Can it integrate BrewDog and Carlsberg without margin dilution? And will the U.S. finally move on rescheduling? For investors, the key takeaway is that the transformation is real, but the market wants proof — not promise — before re-rating the shares.
As Irwin Simon closed the call: “We know what we need to do. We'll focus on delivery.” — Irwin Simon, Chief Executive Officer · 2026-07-28 That shift from vision to execution is precisely what will determine whether Tilray's next chapter is written in the stock market or remains a story of potential unfulfilled.